Neoantigens, also called tumor-specific antigens (TSA), are mutated peptides derived from the expression of mutated genes in tumor cells and presented on the tumor cell surface by major histocompatibility complex (MHC) and subsequently trigger a neoantigen-specific T cell response to destroy tumors. The gene discussed is PRDX2; the disease is neoplasm.